Compare AMCI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMCI | KLRS |
|---|---|---|
| Founded | 2021 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.5M | 113.0M |
| IPO Year | N/A | N/A |
| Metric | AMCI | KLRS |
|---|---|---|
| Price | $4.89 | $4.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 79.5K | 74.5K |
| Earning Date | 04-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.60 | $2.14 |
| 52 Week High | $15.75 | $11.88 |
| Indicator | AMCI | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 53.87 |
| Support Level | $4.06 | $4.27 |
| Resistance Level | $5.74 | $4.80 |
| Average True Range (ATR) | 0.46 | 0.33 |
| MACD | 0.13 | 0.06 |
| Stochastic Oscillator | 32.76 | 94.44 |
AMC Robotics Corp is a technology solutions company that offers AI-powered smart security and robotics solutions. It currently sells smart hardware products designed for residential and commercial use, including smart cameras, driving recorders, action cameras, and Retina K cameras, which are marketed under the YI brand. AMC Robotics is also engaged in developing additional hardware products and technology capabilities, including IoT-enabled devices, AI-based features, wearable devices, and AI robotics. Using its technological capabilities, the company is developing robotic dogs, robotic arms, and robotic unloading systems, offering smart solutions for the logistics and warehousing sectors. It has two primary operating segments: North America, which generates maximum revenue, and Europe.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.